{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:33:35Z","timestamp":1794803615488,"version":"4.9.1"},"reference-count":51,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The prevalence and severity of non-alcoholic fatty liver disease (NAFLD) is increasing, yet adequately validated tests for care paths are limited and non-invasive markers of disease progression are urgently needed. The aim of this work was to summarize the performance of Pro-C3, a biomarker of active fibrogenesis, in detecting significant fibrosis (F \u2265 2), advanced fibrosis (F \u2265 3), cirrhosis (F4) and non-alcoholic steatohepatitis (NASH) in patients with NAFLD. A sensitive search of five databases was performed in July 2021. Studies reporting Pro-C3 measurements and liver histology in adults with NAFLD without co-existing liver diseases were eligible. Meta-analysis was conducted by applying a bivariate random effects model to produce summary estimates of Pro-C3 accuracy. From 35 evaluated reports, eight studies met our inclusion criteria; 1568 patients were included in our meta-analysis of significant fibrosis and 2058 in that of advanced fibrosis. The area under the summary curve was 0.81 (95% CI 0.77\u20130.84) in detecting significant fibrosis and 0.79 (95% CI 0.73\u20130.82) for advanced fibrosis. Our results support Pro-C3 as an important candidate biomarker for non-invasive assessment of liver fibrosis in NAFLD. Further direct comparisons with currently recommended non-invasive tests will demonstrate whether Pro-C3 panels can outperform these tests, and improve care paths for patients with NAFLD.<\/jats:p>","DOI":"10.3390\/biomedicines9121920","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T09:02:19Z","timestamp":1639558939000},"page":"1920","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2101-161X","authenticated-orcid":false,"given":"Anne Linde","family":"Mak","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-527X","authenticated-orcid":false,"given":"Anne-Marieke","family":"van Dijk","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7002-118X","authenticated-orcid":false,"given":"Yasaman","family":"Vali","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[{"name":"Metabolic Liver Research Program, Department of Medicine, University Medical Centre, Johannes Gutenberg University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[{"name":"The Newcastle Liver Research Group, Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Julia","family":"Brosnan","sequence":"additional","affiliation":[{"name":"Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hadi","family":"Zafarmand","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewkoemar","family":"Ramsoekh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Nieuwdorp","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan G.","family":"Holleboom","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic Steatohepatitis: A Review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2017.10.015","article-title":"Pharmacotherapy for NASH: Current and emerging","volume":"68","author":"Konerman","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients with Nonalcoholic Fatty Liver Disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Nasr","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5152\/dir.2018.17525","article-title":"Predictors of bleeding complications following percutaneous image-guided liver biopsy: A scoping review","volume":"25","author":"Midia","year":"2019","journal-title":"Diagn. Interv. Radiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100234","DOI":"10.1016\/j.jhepr.2021.100234","article-title":"European \u2018NAFLD Preparedness Index\u2019\u2014Is Europe ready to meet the challenge of fatty liver disease?","volume":"3","author":"Lazarus","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ueg2.12150","article-title":"Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease","volume":"9","author":"Schattenberg","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/liv.14625","article-title":"Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease","volume":"40","author":"Jayaswal","year":"2020","journal-title":"Liver Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jhep.2015.10.009","article-title":"Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease","volume":"64","author":"Pavlides","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/jmri.27703","article-title":"Assessment of Imaging Modalities against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort","volume":"54","author":"Troelstra","year":"2021","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","article-title":"Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease\u2014Where do we stand?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers","volume":"68","author":"Chalasani","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"EASL (2021). Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"van Kleef, L.A., Sonneveld, M.J., de Man, R.A., and de Knegt, R.J. (2021). Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease\u2014Implications for the clinical utility of the EASL NIT guideline. J. Hepatol.","DOI":"10.1016\/j.jhep.2021.08.017"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","unstructured":"Karsdal, M.A. (2016). Type III Collagen. Biochemistry of Collagens, Laminins and Elastin, Elsevier. [2nd ed.]."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non-invasive biomarkers of liver fibrosis","volume":"40","author":"Karsdal","year":"2020","journal-title":"Liver Int."},{"key":"ref_24","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am. J. Transl. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/00365521.2017.1392596","article-title":"PRO-C3: A new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C","volume":"53","author":"Hansen","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19761","DOI":"10.1038\/s41598-019-56268-3","article-title":"Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer","volume":"9","author":"Willumsen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/1756-185X.13804","article-title":"Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis","volume":"23","author":"Kubo","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","article-title":"Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease","volume":"1","author":"Boyle","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jhep.2021.08.016","article-title":"Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population","volume":"75","author":"Nielsen","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","article-title":"A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients","volume":"116","author":"Eslam","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_35","unstructured":"The Cochrane Collaboration (2014). Review Manager (RevMan), The Nordic Cochrane Centre. Version 5.3."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J. Clin. Epidemiol."},{"key":"ref_37","unstructured":"R Core Team (2021, December 01). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_38","unstructured":"Doebler, P. (2021, December 01). Mada: Meta-Analysis of Diagnostic Accuracy. R Package, Version 0.5.10. 2020. Available online: https:\/\/CRAN.R-project.org\/package=mada."},{"key":"ref_39","first-page":"344","article-title":"Confidence interval for the AUC of SROC curve and some related methods using bootstrap for meta-analysis of diagnostic accuracy studies","volume":"7","author":"Noma","year":"2021","journal-title":"Commun. Stat. Case Stud. Data Anal. Appl."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"van Enst, W.A., Ochodo, E., Scholten, R.J., Hooft, L., and Leeflang, M.M. (2014). Investigation of publication bias in meta-analyses of diagnostic test accuracy: A meta-epidemiological study. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-70"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2337\/dc18-2578","article-title":"Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_42","unstructured":"Knochel, J., Kechagias, S., Bergenholm, L., Liljeblad, M., Daniels, S.J., Leeming, D.J., Nasr, P., Carlsson, B., Ekstedt, M., and Hansson, S. (2020, January 13\u201316). Pro-C3 but not PC3X is increased with advanced fibrosis stage in a longitudinal cohort of non-alcoholic fatty liver disease (NAFLD) patients. Proceedings of the AASLD, Virtual."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12414","DOI":"10.1038\/s41598-018-30457-y","article-title":"An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis","volume":"8","author":"Luo","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/apt.15427","article-title":"Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program","volume":"50","author":"Huber","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100317","DOI":"10.1016\/j.jhepr.2021.100317","article-title":"Determining a healthy reference range and factors potentially influencing PRO-C3\u2014A biomarker of liver fibrosis","volume":"3","author":"Erhardtsen","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"i4428","DOI":"10.1136\/bmj.i4428","article-title":"Non-alcoholic fatty liver disease (NAFLD): Summary of NICE guidance","volume":"354","author":"Glen","year":"2016","journal-title":"BMJ"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"Boursier","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/liv.12700","article-title":"Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C","volume":"35","author":"Nielsen","year":"2015","journal-title":"Liver Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/12\/1920\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:48:41Z","timestamp":1760168921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/12\/1920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["biomedicines9121920"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9121920","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]}}}